Learning outcomes
By the end of this lesson you should be able to: describe the autoimmune lesion in myasthenia gravis and explain why weakness worsens with use; distinguish it from Lambert-Eaton syndrome by the effect of repeated use; define a channelopathy and give two examples with their mechanism; explain why malignant hyperothermia is a channel disease of the muscle calcium-release channel; and predict the effect of an acetylcholinesterase inhibitor in myasthenia gravis and in Lambert-Eaton syndrome.
Prerequisites
Lessons 1-5. You need the safety factor at the neuromuscular junction, the quantal release of acetylcholine, and the channel states of the action potential.
The big idea
Transmission failure is a disease of margins, and the two autoimmune neuromuscular disorders fail in opposite directions. In myasthenia gravis the antibodies destroy the receptors themselves, so transmission fails with repeated use — a muscle works, gets tired, and stops working. In Lambert-Eaton syndrome the antibodies attack the calcium channels on the nerve terminal, so less transmitter is released at first, but repeated firing allows calcium to accumulate in the terminal and the response improves with use. Opposite clinical patterns, both from an antibody against a protein in the same synapse.
Myasthenia gravis
Myasthenia gravis is an auto-antibody disease directed against the postsynaptic nicotinic acetylcholine receptors. Antibodies cross-link the receptors, accelerating their removal from the membrane and blocking the binding site, so the number of functional receptors on the end plate falls. Transmitter is still released normally, but with fewer receptors to bind it, the end-plate potential shrinks — and when it no longer reaches threshold, the muscle fibre fails to contract.
| Feature | Myasthenia gravis | Lambert-Eaton myasthenic syndrome |
|---|---|---|
| Site of the lesion | Postsynaptic — nicotinic ACh receptors | Presynaptic — voltage-gated calcium channels on the nerve terminal |
| Effect on the end-plate potential | Reduced, because fewer receptors | Reduced at first, because less transmitter released |
| Effect of repeated use | Weakness worsens (fatigability) | Strength improves transiently as calcium accumulates in the terminal |
| Typical muscles first | Extraocular and eyelid muscles — drooping eyelids, double vision, difficulty swallowing and speaking | Proximal limb muscles — difficulty rising from a chair, climbing stairs |
| Common associations | Thymoma or thymic hyperplasia; other autoimmune disease | Small-cell lung cancer in many cases |
| Treatment | Acetylcholinesterase inhibitors (pyridostigmine), immunosuppression, thymectomy | Treating the tumour; amifampridine to prolong calcium channel opening; immunosuppression |
The fatigability has a precise explanation, and it is worth understanding rather than memorising. Normal release declines slightly with each successive impulse, a normal physiological decrement. With a healthy safety factor, the end-plate potential remains above threshold despite the decline. In myasthenia the margin is already narrow, so a small normal decline takes it below threshold — and the muscle fails. That is why a patient can rise from a chair but not repeat the rise, and why the drooping eyelid is worse in the evening.
Why does an acetylcholinesterase inhibitor improve strength in myasthenia gravis but worsen symptoms in Lambert-Eaton syndrome?
Channelopathies
| Disorder | Channel affected | Mechanism | Clinical picture |
|---|---|---|---|
| Myasthenia gravis | Nicotinic ACh receptor (ligand-gated) | Auto-antibodies destroy and remove the receptors | Fluctuating weakness, ptosis, diplopia, dysphagia; worse with use |
| Lambert-Eaton syndrome | Presynaptic voltage-gated calcium channels | Auto-antibodies reduce transmitter release | Proximal weakness that improves with use; areflexia; autonomic symptoms |
| Malignant hyperthermia | Ryanodine receptor, the calcium-release channel of the sarcoplasmic reticulum | Volatile anaesthetics trigger uncontrolled calcium release into the muscle cytosol | Rigidity, hyperthermia, acidosis, tachycardia after triggering anaesthetics — treated with dantrolene |
| Myotonia (chloride channelopathy) | Muscle chloride channels | Reduced chloride conductance leaves the muscle membrane hyperexcitable | Delayed relaxation after contraction — difficulty letting go of a handshake |
| Periodic paralysis | Sodium, calcium or potassium channels of muscle | Altered resting excitability | Attacks of flaccid paralysis lasting hours, often triggered by carbohydrate meals or by rest after exercise |
| Long QT syndrome | Cardiac potassium or sodium channels | Prolonged cardiac repolarisation | Syncope or sudden death from torsades de pointes |
Read the table as a general rule: whether a channelopathy causes too much or too little activity depends on the channel and on the direction of the fault. A myasthenia gravis antibody removes receptors, so transmission is too weak; a myotonia mutation leaves the muscle too excitable, so it cannot relax. The same organ — muscle — gives two opposite pictures, because the faulty channel sits at different points in the same chain.
Clinical correlation: malignant hyperthermia
A patient with a susceptibility to malignant hyperthermia receives a volatile anaesthetic and, within minutes of the operation beginning, becomes rigid, their temperature climbs steeply, the carbon dioxide rises, and the heart rate accelerates. The ryanodine receptor of the sarcoplasmic reticulum — the channel that normally releases calcium into the muscle cytosol only in response to a depolarisation signal — has been forced open by the anaesthetic, so calcium floods the cytosol continuously. Sustained contraction, ATP consumption and heat production escalate without limit.
Treatment is dantrolene, which blocks calcium release from the sarcoplasmic reticulum, together with stopping the triggering agent, cooling, and correcting the acidosis and hyperkalaemia that follow the massive calcium release. It is a medical emergency and it is inherited, so a positive family history of an anaesthetic problem is a contraindication to the standard agents.
Common mistakes
Watch outSaying myasthenia gravis attacks the nerve terminal. It attacks the postsynaptic receptor — that is the whole distinction from Lambert-Eaton, and it is what makes the weakness fatigable rather than improving with use.
Watch outSaying the weakness of myasthenia gravis is constant. It fluctuates, characteristically worsens through the day with continued use, and is worst in the continuously active eye and bulbar muscles. Constant weakness from the first symptom suggests a primary muscle disease instead.
Watch outAttributing malignant hyperthermia to an acetylcholinesterase problem or to a defect in the acetylcholine receptor. It is a defect in the sarcoplasmic reticulum calcium release channel, triggered by specific anaesthetics — and it is treated with dantrolene, not an anticholinesterase.
Check your understanding
Why does muscle weakness in myasthenia gravis worsen with repeated use of a muscle?
A patient with proximal limb weakness and absent reflexes reports that their strength improves after a few attempts. Which muscle group is most likely affected first, and what is the likely diagnosis?
What is the mechanism and the specific treatment of malignant hyperthermia?
Multiple choice
Which of these correctly characterises myasthenia gravis?
Which muscle group is usually affected first in myasthenia gravis?
A patient's strength improves as they repeat a movement. What is the most likely diagnosis?
Which drug is given for malignant hyperthermia?
Which is an example of a channelopathy caused by a chloride channel defect?
Module summary and next
This module has covered one continuous chain: how the internal environment is held steady, how the membrane protects a potassium gradient, how that gradient becomes a voltage, how the voltage becomes a spike, and how the spike becomes a chemical message that contracts a muscle. Every failure in that chain is a disease: hyperkalaemia disturbs the gradient, demyelination blocks the spike, botulinum toxin stops the release, and myasthenia gravis destroys the receptors that read the message.
Next module: blood, haemostasis and immunity — where the same themes acquire a tissue-level dimension, from the oxygen-carrying capacity of haemoglobin to the clotting cascade that is itself a positive feedback loop.